Phase 3 Type 2 Diabetes Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who were assigned male or female at birth
- People who are 18 years of age or older at the time of signing the consent form
- People who were diagnosed with type 2 diabetes at least 180 days before the screening visit
- People whose diabetes is currently managed with lifestyle changes (such as diet and exercise) and/or between zero and three approved diabetes tablets — such as metformin, SGLT2 inhibitors, sulfonylureas, or similar medications — taken at a stable dose and frequency before screening
- People whose blood sugar control measure (called HbA1c) falls between 7% and 10%, as confirmed by a central laboratory at screening
Who may not be able to join:
- People whose kidneys are not functioning well enough, based on a specific blood test result falling below a set threshold at screening
- People who have diabetes-related eye disease (affecting the retina or the central part of the eye) and have already received eye treatments such as laser therapy, eye surgery, or certain injections — or who are expected to need those treatments during the trial. An eye examination is required within 90 days before screening or between screening and joining the trial (confirm with trial site for specific examination requirements)
- People who have a condition called "hypoglycaemic unawareness," meaning they do not notice the warning signs when their blood sugar drops too low, as assessed by the trial doctor using a specific questionnaire
- People who have had repeated serious episodes of very low blood sugar (severe hypoglycaemia) within the past year, as determined by the trial doctor
- People who have previously used certain injectable or oral diabetes medications that work through a specific hormone pathway (GLP-1 receptor agonists, dual GLP-1/GIP receptor agonists, or amylin analogues) before the screening visit
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Phone: (+1) 866-867-7178
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Relative change in body weight
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.